Akoya Biosciences, Inc. (AKYA) said it expects fourth quarter revenue to be between $25.5 million and $26.5 million, as compared to $21.2 million a year ago. For fiscal 2023, the company expects revenue to be between $95.6 million and $96.6 million, as compared to $74.9 million, last year. Year end 2023 projected cash, cash equivalents, and restricted cash balance is between $83.0 million and $85.0 million.
Brian McKelligon, CEO, Akoya Biosciences, said: "Throughout 2023, we delivered strong financial performance on the topline while maintaining operating expenses at a steady level, bolstering our confidence in achieving cash flow positivity earlier than previously projected."
Akoya Biosciences expects 2024 revenue to grow more than 20% and projects achieving operating cash flow breakeven by year end 2024.
For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.